ADVANCES IN THE DIAGNOSIS PATHOGENESIS AND TREATMENT OF CIDP PDF
Download Citation on ResearchGate | Advances in the diagnosis, pathogenesis and treatment of CIDP | Chronic inflammatory demyelinating. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens. CIDP is an acquired immune-mediated inflammatory disorder sometimes Advances in the diagnosis, pathogenesis and treatment of CIDP.
|Published (Last):||2 December 2012|
|PDF File Size:||4.77 Mb|
|ePub File Size:||20.30 Mb|
|Price:||Free* [*Free Regsitration Required]|
Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.
References Publications referenced by this paper. Skip to search form Skip to main content.
Advances in the diagnosis, pathogenesis and treatment of CIDP.
Citations Publications citing this paper. An open label clinical trial of complement inhibition in multifocal motor neuropathy. Despite clinical challenges in diagnosis—owing in part to the advabces of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination—consensus criteria seem to have been reached for research or clinical practice.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Immunoglobulins, Intravenous Demyelinating peripheral neuropathy Polyneuropathy. This paper has been referenced on Twitter 1 time over the past 90 days.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Search for additional papers on this topic. Topics Discussed in This Paper.
Advances in the diagnosis, pathogenesis and treatment of CIDP
Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy.
Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Chronic inflammatory demyelinating polyneuropathy CIDP is the most common chronic autoimmune pqthogenesis. Maintenance therapy with IVIg can induce sustained remission, increase quality of life and prevent further axonal loss, but caution is needed to avoid overtreatment.
This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens, and discusses current treatments, ongoing challenges and future therapeutic directions.
New biomarkers and scoring systems represent emerging tools with the potential to predict therapeutic responses and identify patients with active disease for enrollment into clinical trials. Dalakas The Lancet Neurology BoumpasGeorge K.
Advances in the diagnosis, pathogenesis and treatment of CIDP – Semantic Scholar
MRI assessment including apparent diffusion coefficient. Brannagan Journal of the peripheral nervous system: Advances in our understanding of the underlying immunopathology in CIDP have identified new targets for future therapeutic efforts, including T cells, B cells, and transmigration and transduction molecules.
Despite clinical challenges in diagnosis-owing in part to the dizgnosis of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination-consensus criteria seem to have been reached for research or clinical practice.
Evidence from Human and Animal Studies: From This Paper Figures, tables, and topics from this paper. Showing of references.
An update on the management of chronic inflammatory demyelinating polyneuropathy. Current diagnosis of CIDP: Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy Marinos C.